Neuronetics announced an expanded commercial partnership with Transformations Care Network, TCN, one of the nation’s largest mental health care providers. Under the new agreement, Neuronetics will be the exclusive supplier of new transcranial magnetic stimulation equipment to TCN, increasing its NeuroStar TMS footprint and availability to patients. “We are delighted to be extending our commercial relationship with TCN, a long-standing, valued customer with a commitment to providing the best care for their patients,” said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics. “With the continued increase in the need for mental health services, we’re glad that NeuroStar TMS is a significant part of TCN’s plan to grow and strengthen mental healthcare in their communities.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on STIM:
- Neuronetics Inc Boosts Executive Compensation for Top Leaders
- Neuronetics price target raised to $8 from $7 at Piper Sandler
- Neuronetics Inc Shares New Investor Insights Online
- Neuronetics reports Q4 EPS (19c), consensus (26c)
- Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results